Withings' Body Scan 2 is on sale in the US as of today, priced at $600 and available for order through the company's website Engadget. The launch closes a gap between the device's CES debut in January, when Withings targeted a second-quarter 2026 release MacRumors, and its actual US availability, which slipped behind that window while the product cleared FDA review.

The scale has been on the market longer elsewhere. Withings launched Body Scan 2 in Europe on or before June 10, priced at €499.95 Gadgets & Wearables, and in the UK at £449.95, per a company press release dated June 9 Withings UK press release. The US price sits above both once converted, consistent with Withings' historical pattern of charging a premium in its home-turf-adjacent US market for connected health hardware.

Withings' central claim is that Body Scan 2 delivers data quality comparable to a clinical DEXA scan, a body-composition benchmark typically requiring a dedicated imaging suite Engadget. The device analyzes 60 biomarkers in a single session, up from 40 on the original Body Scan, and Withings' US landing page states the full panel completes in 90 seconds Withings US landing page. That figure has not appeared in a dated press release, so it should be read as the manufacturer's own specification rather than an independently verified benchmark.

The underlying sensing approach combines two techniques. Bioimpedance Spectroscopy (BIS) sends current across 13 frequencies through electrodes embedded in a retractable handle and the scale's tempered-glass plate, extracting total body water, cellular age, active cell mass, and metabolic efficiency Withings UK press release. Impedance Cardiography (ICG), new to this generation, assesses the heart's capacity to pump blood to organs Engadget. Together they feed a "Health Trajectory" feature — a predictive model built from the biomarker set that Withings positions as the scale's headline differentiator Withings US landing page.

Two capabilities required separate FDA clearance before US sale: hypertension risk notifications and a six-lead EKG for atrial fibrillation detection The Verge. Both are now active, and Withings has confirmed the company secured the necessary US regulatory approvals ahead of today's sale Engadget. A third feature, a Diabetes Risk Score, remains in development and is still pending FDA review, meaning it launched in the UK without US equivalence and won't ship domestically until cleared Withings UK press release.

Firmware version 1491, documented in Withings' support portal, adds Longevity Scan and Daily Scan measurement modes along with blood oxygen readings Withings support article. The distinction between the two scan modes suggests Withings is segmenting the device's use case between quick daily check-ins and a deeper, less frequent longevity-oriented panel — though the company has not detailed exactly how the two modes differ in sensor duty cycle or biomarker coverage.

Notably, as of this writing Withings' own US landing pages still carry language inconsistent with a live product. The page at withings.com/us/en/landing/body-scan-2 displays an "Available soon" badge and an explicit disclaimer that "Body Scan 2 is not currently available for sale or distribution" Withings US landing page. A companion "unveiled" page similarly solicits email sign-ups under an "Available soon" badge rather than a purchase link Withings unveiled landing page. Whether this reflects a staged rollout, a lagging content update, or region-specific gating within Withings' own site architecture is not clear from available sources — but it is worth flagging for anyone attempting to buy directly from Withings rather than through the retail channel Engadget describes.

Withings' marketing frames Body Scan 2 as "the first science-backed longevity station," a positioning reinforced by an endorsement from Dr. Platzer, a physician specializing in preventive, nutritional, and longevity medicine, and by explicit callouts to chronic stress, sedentary routines, midlife visceral fat gain, perimenopause and menopause, athletic training, and GLP-1 weight-loss treatment monitoring Withings US landing page. That messaging places the product squarely inside the consumer longevity category that has drawn Apple, Oura, and a wave of venture-backed startups over the past two years, all competing to turn periodic clinical-style testing into a subscription habit.

The $600 hardware price is only the entry point. Body Scan 2 ships with a one-month free trial of Withings+, the company's premium subscription tier for ongoing health monitoring and trend analysis Engadget. Withings has not published post-trial Withings+ pricing in any of the sources reviewed here, which leaves the actual cost of using the scale's full feature set, including the Health Trajectory model, unresolved for prospective buyers evaluating total cost of ownership against dedicated DEXA scans or InBody clinical devices.

The broader significance of at-home bioimpedance and cardiac sensing reaching this granularity is less about any single biomarker and more about the compounding effect of longitudinal data. A DEXA scan captures a moment; a scale used daily, or even weekly under the Longevity Scan mode, builds a trend line. Whether that trend line changes clinical behavior, or simply generates another stream of data most users glance at once and ignore, is the question that will determine whether the longevity-station category outlasts its current marketing cycle.